Paul Eckburg's most recent trade in AN2 Therapeutics Inc was a trade of 60,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 15, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Paul Eckburg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Paul Eckburg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 30,000 | 51,416 | - | 0 | Common | |
| AN2 Therapeutics Inc | Paul Eckburg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 30,000 | 51,416 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Paul Eckburg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 70,950 | 70,950 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Paul Eckburg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 66,000 | 66,000 | - | - | Stock Option (right to buy) |